BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 20464667)

  • 1. Fabry disease - Vascular manifestations.
    Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
    Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease with atypical neurological presentation: report of a case.
    Simoncini C; Orsucci D; Gori S; Giorgi FS; Cosottini M; Siciliano G; Mancuso M
    Neurologist; 2012 Nov; 18(6):413-4. PubMed ID: 23114679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroenterological complications of Anderson-Fabry disease.
    Buda P; Książyk J; Tylki-Szymanska A
    Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: A fundamental genetic modifier of cardiac function.
    Tadevosyan A
    Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment.
    Mahmud HM
    J Pak Med Assoc; 2014 Feb; 64(2):189-94. PubMed ID: 24640811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.